Although there may be some activity in EGFR exon 20 insertion NSCLC, particularly at the 160 mg dose, it is not comparable with the efficacy of osimertinib in patients with the canonical Ex19del and L858R activating mutations in EGFR. The bispecific EGFR-MET monoclonal antibody amivantamab and the EGFR TKI mobocertinib are currently approved as second-line therapy.22 Here, MET is linked to non-small cell lung carcinoma.